Lack of defined apheresis collection criteria in publicly available <scp>CAR‐T</scp> cell clinical trial descriptions: Comprehensive review of over 600 studies-Reference-Cited by-同舟云学术

Lack of defined apheresis collection criteria in publicly available CAR‐T cell clinical trial descriptions: Comprehensive review of over 600 studies

Published:2022-01-27 Issue:3 Volume:37 Page:223-236
ISSN:0733-2459
Container-title:Journal of Clinical Apheresis
language:en
Short-container-title:J of Clinical Apheresis

Author:

Thibodeaux Suzanne R.¹^ORCID,Aqui Nicole A.²,Park Yara A.³,Schneiderman Jennifer⁴,Su Leon L.⁵^ORCID,Winters Jeffrey L.⁶,Zubair Abba C.⁷^ORCID,Schwartz Joseph⁸,Liu Hien D.⁹,

Affiliation:

1. Department of Pathology and Immunology Washington University School of Medicine St. Louis Missouri USA

2. Department of Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

3. Department of Pathology and Laboratory Medicine University of North Carolina Chapel Hill North Carolina USA

4. Department of Pediatric Hematology/Oncology/Neuro‐oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago Northwestern University Feinberg School of Medicine Chicago Illinois USA

5. Department of Pathology and Laboratory Medicine Phoenix Children's Hospital Phoenix Arizona USA

6. Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA

7. Laboratory Medicine and Pathology and Center for Regenerative Medicine Mayo Clinic Jacksonville Florida USA

8. Department of Pathology, Molecular and Cell‐Based Medicine Icahn School of Medicine New York New York USA

9. Department of Bone Marrow Transplant and Cellular Immunotherapy H. Lee Moffitt Cancer Center Tampa Florida USA

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jca.21964

Reference20 articles.

1. Kymriah[package insert]. East Hanover NJ. Novartis Pharmaceuticals Corporation; 2017 revised May 2018.

2. Yescarta[package insert]. Santa Monica CA: Kite Pharma Inc.; 2017.

3. Tecartus[package insert]. Santa Monica CA: Kite Pharma Inc.; 2020.

4. Breyanzi[package insert]. Bothell WA: Juno Therapeutics Inc a Bristol‐Myers Squibb Company; 2021.

5. Abecma[package‐insert]. Summit NJ: Celgene Corporation a Bristol‐Myers Squibb Company; 2021.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk-Based Qualification of Cellular Starting Material Collection Sites: Tools to Determine Scope of Manufacturer Audits and Reduce Duplicative Efforts;Transplantation and Cellular Therapy;2024-09

2. A multi‐institutional survey of apheresis services among institutions in the United States;Journal of Clinical Apheresis;2024-07-09

3. Mobilization and collection of CD34 + cells in patients with globin disorders: Providing the starting material to manufacturers of autologous gene therapies;Transfusion and Apheresis Science;2024-06

4. Collection efficiency and safety of large‐volume leukapheresis for the manufacturing of tisagenlecleucel;Transfusion;2024-02-28

5. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies;Transplantation and Cellular Therapy;2024-02